CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Michael Weiss

Chairman, Chief Executive Officer & President, TG Therapeutics, Inc.

Search every verified Michael Weiss interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Weiss, Chairman, Chief Executive Officer, and President of Iteos Therapeutics, discussed the company's performance and outlook during TG Therapeutics' fourth-quarter 2025 earnings call. He reported approximately $616 million in total global revenue for 2025, with $594 million from U.S. net sales of Briumvi, and described the year as one of scaling and strengthening the company. Weiss also noted the completion of a $100 million share repurchase program, the authorization of an additional $100 million, and stated that he views the shares as undervalued relative to expected cash flow. He highlighted anticipated catalysts for 2026, including topline data from an enhanced trial, preliminary data from a program called Azerell, and pivotal data for a subcutaneous Briumvi program expected late in the year or early next. In earlier appearances, Weiss discussed the company's clinical development strategy and commercial plans. He described delivering positive phase three data in 2020 for marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, with the first approval for the first two indications in 2021. He also spoke about using price as a lever for market access in multiple sclerosis, citing payer research and a willingness to offer a discount from current pricing. In 2015 interviews, he emphasized the goal of removing chemotherapy from treatment regimens through combination therapies and discussed the importance of pricing innovation responsibly, distinguishing between innovative and generic drugs in the context of political debates over drug costs.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →